Want to track EOLS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
EOLS earnings report is expected in 8 days (11 Mar 2026)
Evolus reports first-ever adjusted profit in Q2 fueled by strong sales of Botox rival
Evolus , an anti-wrinkle injection maker, reported its first-ever quarterly profit on an adjusted basis on Wednesday, driven by strong sales of its Botox rival Jeuveau.
Reuters | 1 year ago
Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early
Medical aesthetics company Evolus notched its first-ever profits late Wednesday — two quarters ahead of expectations.
Investors | 1 year ago
Evolus (EOLS) Releases Favorable Dermal Fillers Study Data
The addition of Evolysse fillers to the company's portfolio complements Evolus' (EOLS) flagship neurotoxin Jeuveau.
Zacks | 1 year ago
